Genetic Variant Increases Risk of Chronic Rejection in Lung Transplant Patients
Table of Contents
About one-third of lung transplant recipients carry a genetic variant that increases their likelihood of developing chronic lung allograft dysfunction (CLAD), the leading cause of mortality after lung transplantation. A recent study led by UCLA Health has identified a potential cause: a variant in the C3 gene,which impairs the body’s ability to regulate the complement system – a crucial part of the immune system.
Understanding the Link Between C3 Gene Variant and Rejection
“Lung transplantation has the poorest long-term survival of any solid organ transplant, and that’s largely because of chronic rejection,” said dr. Hrish Kulkarni, the Allan J. Swartz and Roslyn Holt Swartz Women’s Lung Health Endowed Chair and associate professor in the Division of Pulmonary,Critical Care and Sleep Medicine at the David Geffen School of Medicine at UCLA. UCLA Health News He is also the corresponding author of the study, published in The Journal of Clinical Investigation.
“We wanted to understand why certain patients are more vulnerable to chronic lung organ rejection than others, and uncover new biological pathways that could led to more effective therapies and, ultimately, better long-term outcomes for our patients.”
Study Findings and Mechanism of Rejection
The study analyzed data from two autonomous groups of lung transplant recipients. Researchers found that approximately one-third of patients in both cohorts carried the C3 gene variant. These patients were considerably more likely to experiance chronic rejection, particularly if they also had pre-existing antibodies against the donor lungs.
To investigate the underlying mechanism, researchers utilized a mouse model of lung transplantation designed to mimic the impaired complement regulation seen in patients with the C3 variant. Their experiments revealed that the variant causes the complement system to activate specific B cells, leading to the production of antibodies that attack the transplanted lung. This process is not fully controlled by current anti-rejection medications.
The Role of the Complement System
The complement system is a vital part of the immune system that helps clear infections and debris. However, in the context of organ transplantation, it can mistakenly identify the transplanted organ as foreign and initiate an immune response leading to rejection.The C3 gene plays a critical role in regulating this system, and variations in the gene can disrupt this regulation.
Future implications and Personalized Therapies
“We hope these findings pave the way for new,more personalized therapies for chronic lung rejection,a disease that currently has no cure,” Kulkarni said. UCLA Health News
Identifying the C3 gene variant as a risk factor opens the door to potential screening methods for transplant candidates. This could allow clinicians to tailor immunosuppressive regimens to individual patients, possibly improving long-term outcomes and reducing the incidence of chronic rejection.